Dry Eye Disease: The Evidence-Based Supplement Protocol

← Back to articles

Dry eye disease is multifactorial — meibomian gland dysfunction, aqueous-deficient tear film, and inflammatory components all coexist in varying proportions. Topical management (artificial tears, anti-inflammatory drops, punctal plugs) remains first-line. Supplements have a defined role primarily targeting the inflammatory and meibomian-secretion components.

Omega-3 — Lower Dose for Symptoms, Higher Dose Mixed

The DREAM trial in 535 adults with moderate-to-severe dry eye randomized to 3,000 mg fish oil daily versus placebo for one year. The primary outcome (OSDI symptom score) was statistically null between arms — both improved, suggesting a strong placebo or regression-to-mean effect. However, multiple smaller trials and a 2019 Cochrane review concluded omega-3 produces modest improvements in tear breakup time and Schirmer scores. Effective doses cluster at 1,000–2,000 mg EPA + DHA daily; very high doses do not add benefit. See our omega-3 form piece.

Vitamin A — Repletion in Deficiency Only

Frank vitamin A deficiency produces xerophthalmia (the original dry eye) and remains a cause of pediatric blindness in low-income settings. In Western adults, deficiency is rare and routine vitamin A supplementation does not improve dry eye. The topical retinyl palmitate eye drop (Vita-Pos) has some trial support for meibomian gland function. Oral supplementation only if labs confirm deficiency.

Lactoferrin, 270 mg Daily

Lactoferrin is naturally present in tears and has antimicrobial, anti-inflammatory, and tissue-repair functions. A 2020 Japanese RCT in 80 adults with Sjogren-related dry eye showed lactoferrin 270 mg daily improved Schirmer scores and corneal staining versus placebo over 8 weeks. The trial is small and mostly Japanese, replication ongoing. See our lactoferrin piece.

Vitamin D — Repletion in Deficiency

Lower serum 25-OH-D is associated with dry eye severity in observational data. The 2016 Yoon trial in 105 adults with low 25-OH-D showed repletion improved tear breakup time and Schirmer scores versus placebo. Effect concentrated in deficient adults. Treat the deficiency, not the level.

What NOT to Take

Skip high-dose vitamin A (≥10,000 IU) — chronic high intake causes its own ocular problems (papilledema, hepatic toxicity). Avoid "eye health" megaformulas with subclinical doses of 8+ ingredients. Skip flaxseed oil as an omega-3 substitute for dry eye — ALA→EPA conversion is too inefficient to reach trial-effective doses. Don't replace topical anti-inflammatory drops (cyclosporine, lifitegrast) with oral supplements alone in moderate-severe disease.

How to Run the Protocol

Optimize the topical layer first (artificial tears, lid hygiene, warm compresses for meibomian dysfunction). Get baseline 25-OH-D. Start omega-3 1,500 mg EPA + DHA daily for 12 weeks. Add lactoferrin 270 mg daily if Sjogren-pattern or autoimmune dry eye. Replete vitamin D if low. Re-evaluate OSDI score at 12 weeks; meaningful response is 12+ point reduction. See the dry eye condition page for the wider clinical context.